The Pediatric Acute Leukemia (PedAL) Screening Trial – A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat – A Leukemia & Lymphoma Society and Children’s Oncology Group Study

Inclusion Criteria:

Patients must be less than 22 years of age at the time of study enrollment

Patient must have one of the following:

Patient has known or suspected relapsed/refractory (including primary refractory) AML

This includes isolated myeloid sarcoma
Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome

Patient has known or suspected relapsed ALL that meets one of the following criteria:

Second or greater B-ALL medullary relapse, excluding KMT2Ar.
Any first or greater B-ALL medullary relapse involving KMT2Ar.
Any first or greater T-ALL medullary relapse with or without KMT2Ar.
Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia (MPAL)
Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment-related AML (t-AML) or treatment-related myelodysplastic syndrome (t-MDS)
Patient has known or suspected de novo or relapsed/refractory (including primary refractory) myelodysplastic syndrome (MDS)
Patient has known or suspected de novo or relapsed/refractory (including primary refractory) juvenile myelomonocytic leukemia (JMML)
All patients and/or their parents or legal guardians must sign a written informed consent
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met